Overview

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purposes of this study are to determine: - the safety of pemetrexed and any side effects that might be associated with it - how much pemetrexed should be given to patients. It is possible that information collected during this study will be analyzed by the Sponsor in the future to evaluate pemetrexed for other possible uses or for other medical or scientific purposes other than those currently proposed. Although pemetrexed has been shown to be effective in some patients with non-small-cell lung cancer, pemetrexed might not have beneficial effects for all patients.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Pemetrexed
Criteria
Inclusion Criteria:

- Diagnosis of locally advanced or metastatic (Stage III or IV at entry) non-small cell
lung cancer (NSCLC) that is not amenable to curative therapy.

- Patients must have been previously treated with one platinum-containing chemotherapy
regimen for locally advanced or metastatic disease. Patients are also eligible if they
have received one platinum-based chemotherapy regimen as neoadjuvant or adjuvant
chemotherapy, but must have received an additional chemotherapy regimen upon
recurrence.

- No more than two prior systemic anti-cancer therapies will be allowed.

- Prior radiation therapy is allowed to less than 25% of the bone marrow. Prior
radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at
least 2 weeks before study enrollment, and the patient must have recovered from the
acute toxic effects of the treatment prior to study enrollment.

Exclusion Criteria:

- Pregnancy.

- Breast-feeding.

- Second primary malignancy that is clinically detectable at the time of consideration
for study enrollment.

- Inability to interrupt aspirin, or other nonsteroidal anti-inflammatory agents for a
5-day period.

- Inability or unwillingness to take folic acid or vitamin B12 supplementation.